After Prime Medicine, What’s the Next Gene Editing IPO?

After Prime Medicine, What’s the Next Gene Editing IPO?

Investors enjoyed record numbers of biotech IPOs in 2020 and 2021, as companies rushed to grab bags of money from public markets awash with liquidity. The pipeline will have dried up considerably in 2022, mainly due to tighter financial conditions. It’s not that much fun, but it’s a sign of healthy markets.

Despite the slowdown, the most promising companies are still able to generate enough investor interest to make the numbers work. Prime Medicine (PRME) became one of the largest biotech IPOs of 2022 when it raised $175 million in October. The company is developing a third-generation gene editing technology platform that could potentially avoid the drawbacks of tools currently used in clinical trials. On the other hand, the company will face new challenges for its tools.

.

You Might Also Like:

Leave a Reply

Your email address will not be published. Required fields are marked *